Double-blind and Placebo-controlled Study on Intervention Effect of Medium and Long Chain Fatty Acid Triglyceride on Glycolipid Homeostasis in Patients With Metabolic Syndrome and Mechanisms

Double-blind and placebo-controlled study on intervention effect of medium and long chain fatty acid triglyceride on glycolipid homeostasis in patients with metabolic syndrome and mechanisms

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Syndrome Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutritional and Metabolic Diseases

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Lanxi Traditional Chinese Medicine Hospital

Jinhua, Zhejiang, 321102, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosed metabolic syndrome according to IDF diagnostic criteria;
Rarely eating out of home;
Aged between 40 and 70 years.

Exclusion criteria

Breastfeeding or pregnancy;
History of heart disease, coronary heart disease, stroke, cerebral infarction, viral liver disease (hepatitis A, hepatitis B, etc.), chronic kidney disease (GFR<60 ml/min) or cancer;
Diabetic ketoacidosis or hyperketosis;
Drug use has changed in the past six months;
Taking insulin;
Used MLCT edible oil in the past six months;
Have participated in other clinical trials in the last three months.

Treatment and study plan

MLCT supplementation

Dietary Supplement

MLCT 25g/d for 6 months

Olive Oil

Dietary Supplement

Matching placebo (olive oil) 25g/d for 6 months

Primary outcomes

Change in blood glucose from baseline

Time frame: 6 months

The investigators will measure HbA1c and fasting plasma glucose levels in blood samples before and after treatment.
Change in blood lipids from baseline

Time frame: 6 months

The investigators will measure Triglycerides (TG), total cholesterol (TC), LDL-C, and HDL-C levels in blood samples before and after treatment.

Sponsors and collaborators

Lead sponsor

Zhejiang University

Other

Registry information

Important dates

Study start: 2023
Primary completion: 2023
Study completion: 2023
First posted: Jan 18, 2024
Registry last updated: Mar 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed